Dry Age-Related Macular Degeneration AMD Market Analysis

In-depth Analysis of Dry Age-Related Macular Degeneration AMD Market Industry Landscape

Age-related Macular Degeneration (AMD) stands as a prevalent disorder, particularly among the elderly population. A report from the BrightFocus Foundation in the US highlighted that the dry form of AMD accounts for approximately 90% of all diagnosed cases. In the US alone, statistics from January 2019 indicated that over 11 million individuals were affected by AMD, a number projected to double to around 22 million by the year 2050. Similarly, on a global scale, the prevalence of AMD is anticipated to surge significantly, escalating from approximately 196 million cases in 2020 to an estimated 288 million cases by 2040, according to the same report.

The concerning trend of escalating AMD cases extends to China as well. The report highlighted a substantial increase in AMD cases within the Chinese population. In 2020, the reported cases stood at 31.23 million, a figure projected to skyrocket to approximately 55.19 million by 2050. Notably, a majority of these cases are expected to be the dry form of AMD, emphasizing its predominant presence within the affected population.

These projections paint a concerning picture of the escalating prevalence of AMD, both in the US and globally, including China. The substantial increase in diagnosed cases, particularly the dry form of AMD, poses significant challenges for healthcare systems worldwide. Addressing this growing burden of AMD necessitates a proactive approach, including advancements in research, innovative treatments, and enhanced accessibility to healthcare services. The rise in AMD cases underscores the urgency of collaborative efforts in the medical community to develop effective interventions and preventative measures to manage and mitigate the impact of this widespread eye disorder, ensuring improved outcomes and quality of life for affected individuals in the years to come.

In 2018, healthcare spending in the US averaged more than $10,000 per resident, surpassing all other OECD countries by a significant margin, even when accounting for different purchasing powers across nations. Switzerland, the next highest spender among OECD nations, allocated less than 70% of this amount, while the average spending for all OECD countries amounted to less than 40% of the US figure, totaling $3,994. Government expenditures on healthcare, coupled with policies governing healthcare facilities, access to essential medications, and disposable income availability, play pivotal roles in fostering patient adherence to available treatments. Besides public investment, substantial contributions from manufacturers, venture capitalists, and the introduction of new products in the global intracranial hemorrhage diagnosis and treatment market are anticipated to drive market growth.

The landscape of healthcare investments demonstrates a surge in funding, particularly in the health technology sector. The 2019 Year End Asia Pacific Health Tech Investment Landscape Report by Galen Growth revealed that health tech funding in Asia reached an impressive $5 billion across 340 deals. This substantial increase in healthcare spending is expected to positively impact market growth. A Statista report from October 2020 highlighted China's remarkable healthcare expenditure surge, escalating from under 500 billion yuan in 2000 to over 6.5 trillion yuan in 2019. Such substantial increases in healthcare spending are foreseen to catalyze growth within the dry AMD market.